Biotech funding has returned. The bar has moved with it.
For biotech sponsors, the question worth asking is not whether the rebound is real, but what it is actually rewarding.
Newsletters and Deep Dive digital magazine
For biotech sponsors, the question worth asking is not whether the rebound is real, but what it is actually rewarding.
The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.
Behaviour is the layer that lifestyle, physical performance, and nutrition – together – occupy.
2026 marks a significant evolution for BIO-Europe.
AI has kickstarted a new wave of innovation in biopharma R&D.
Editor's Picks
Newsletters and Deep Dive
digital magazine